Dementia
Conditions
Keywords
neuropsychiatric symptoms, dementia, telemedicine, long-term care facilities
Brief summary
Telemedicine may facilitate adequate treatment of Neuropsychiatric symptoms (NPS) by identifying underlying causes and tailoring a treatment plan (pharmacological or non-pharmacologic treatments including provision of staff education and support, training in problem solving, and targeted therapy directed at the underlying causes for specific behaviors).
Detailed description
During a 6-months period, patients will be included in both arms, whenever they present a disruptive NPS that requires a specialist consultation based on the long-term care facility (LTCF) staff judgment. In the intervention group, a telemedicine (TM) consultation between the LTCF staff (medical and nurse staff) and the Memory Center from the University Hospital, will occur at inclusion (T0). Then, a second TM consultation will occur at 1 month (T1). In the control group management of NPS will be done as usual care. In both groups, patients' parameters such as non-programmed hospitalizations and/or consultations due to disruptive NPS, psychotropic drugs use, and health costs, will be evaluated at inclusion, 1 month and at 2 months. Acceptability of the TM among the LTCF staff will be assessed during the study in the intervention group. The two university hospitals are composed of a group of institutions for elderly people located near Toulouse and Limoges.
Interventions
PROCEDUREtelemedicine
psycho-behavioural care by telemedicine
Sponsors
University Hospital, Toulouse
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient aged 65 or more, with a dementia diagnosed by a specialist or the general practitioner; * patient presenting with a disruptive NPS as defined in French Haute Autorité de Santé (HAS) recommendations (2009), that requires a specialist consultation based on the LTCF staff judgment; * informed and written consent by the patient or the legal representative or the reliable person when appropriate; * general practitioner agreement.
Exclusion criteria
* patient's life expectancy less than 6 months; * Non agreement of study participation of patients or legal representative or the reliable person when appropriate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability of the TM among the LTCF staff | 6 months | Acceptability of the telemedicine (TM) among the LTCF staff which will be assessed in the intervention group by quantitative indicators (proportion of the solicitation of the TM solution among patients with disruptive NPS, the delay to obtain a TM consultation and the number of the staff participants at each TM consultation) and qualitative indicators (staff global satisfaction will be evaluated by focus groups and interviewing). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of non-programmed hospitalizations and/or consultation due to disruptive NPS | 6 months | Calculation of the rate of non-programmed hospitalizations and/or consultation due to disruptive NPS in both groups |
| The psychotropic drugs used | 6 months | Description of psychotropic drugs used in both groups |
| describe the health costs | 6 months | Description of the health costs in both groups |
| describe the estimation of the cluster effect (design effect) | 6 months | Estimation of the cluster effect (design effect) in both groups |
Countries
France
Outcome results
None listed